12/01/2012

Anapharm Europe acquires a new high sensitivity equipment

The new equipment allows the determination of extremely low concentration of compounds such as Fluticasone, Salmeterol, Budesonide, Formoterol, Tiotropium, Ethinyl Estradiol, Paricalcitol, etc. In biological fluids.

As part of its efforts to continue to support drug development of women health and inhaler products, Anapharm Europe has purchased a new equipment targeted for method validation with limits of quantification in the low pg/mL level. The AB SCIEX QTRAP 5500 increases our capabilities for the determination extremely low concentrations of compounds such as Fluticasone, Salmeterol, Budesonide, Formoterol, Tiotropium, Ethinyl Estradiol, Paricalcitol, etc. in biological fluids.

MORE NEWS

31/03/2020 10:03

Anapharm Bioanalytics Brazilian ANVISA Certificate Renewal

Anapharm Bioanalytics is proud to announce that it has recently (February 20th, 2020) renewed its ANVISA (Brazil) certificate. The renewed certification is valid until February 20th, 2022.

READ MORE
27/01/2020 16:02

Anapharm Bioanalytics Receives Certification for French Research Tax Credit

Anapharm Bioanalytics is pleased to announce it has renewed its French research Tax Credit certification (Crédit d’Impôt Recherche) for period 2020 – 2024.

READ MORE
12/06/2019 16:28

Anapharm Bioanalytics’ successful FDA Inspection

Anapharm Bioanalytics is proud to announce that it has successfully undergone another US FDA inspection at its Barcelona based bioanalytical lab. The inspection, that took place in June 2019, had a focus on a total of 8 studies. This was the second unannounced FDA inspection at our facilities without any observations; no 483 form issued.

READ MORE